Articles Tagged with Pfizere settles for Off Label Marketing

Pfizer Inc. has agreed to pay the United States $14.5 million to settle a whistleblower lawsuit alleging improper marketing of the prescription drugs Detrol and Detrol LA. Detrol was approved by the FDA for over active bladder with symptoms of urge incontinence. The lawsuit said Pfizer marketed the drug to men who were suffering from symptoms of benign prostate hyperplasia (enlarged prostate). The whistleblowers David Wetherhold and Marci Drimer will receive 27% of the recovery, $3.9 million.